pashtun

VSAR - Long Opportunity

NASDAQ:VSAR   None
Versartis Inc, had a clinical trial that failed, same deal with AXON and few others, but they still have 3 or 4 trials pending. Dont think it would fall lower. If they have trials left but not that good at these kind of plays. Keep an eye on this one forsure. Might just hold a small lot, 52 week high was 24 $.
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。